Applying Dry Powder Coatings - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Applying Dry Powder Coatings
The authors experiment with a resonant acoustic mixer as a method for dry powder coating.


Pharmaceutical Technology
Volume 35, Issue 10, pp. 94-102

Efficient handling and transport of fine-particle powders can be difficult because of the highly cohesive nature of the bulk powder mass. It is well reported in the literature that the application of nanosized guest dry powder coatings, such as silicon dioxide, onto the surfaces of these cohesive host particles can effectively reduce the attractive forces between them (1–5). The fine nanoparticles increase the spacing between the host particles and increase the apparent surface roughness, which decreases the host particle cohesive van der Waals attractions (5, 6). After dry powder coating, the bulk powder exhibits increased bulk density, improved powder flow performance, and easy fluidization behavior, all of which can significantly improve manufacturing performance (1–5). This result is of significant benefit to pharmaceutical powder processing because the easy transport of large bulk quantities of powder through unit operations is necessary to manufacture solid dosage forms such as capsules and tablets.

It was recently demonstrated that conventional pharmaceutical processing equipment, namely a comil, can effectively apply dry powder coatings of silicon dioxide onto active pharmaceutical ingredients (APIs) and excipients without causing attrition of the host's primary particles (1). This discovery is important because comils can be operated in a continuous manufacturing process and are commonly available at pharmaceutical product manufacturing sites. Although the comil is a simple, effective, and scalable unit operation for applying dry powder coatings, the systematic study of the process operational design space, such as screen size and impeller speed, may be required to optimize the coating performance. This iterative method may not be possible in early drug product development because of the limited available quantities of API (often less than 50 g) and the potential for improved performance after dry powder coating may be overlooked, especially as API synthesis, isolation, and sizing processes change often. Therefore, alternative (or complementary) methods for applying dry powder coatings would be desirable during early product development.


Figure 1: Laboratory-scale resonant acoustic mixer (LabRAM), including the vacuum–deaeration unit (left), mixing unit (center), and control unit (right). (FIGURE 1 IS COURTESY OF RESODYN CORPORATION)
A laboratory scale resonant acoustic mixer (LabRAM) similar to the one shown in Figure 1 was evaluated as a potential tool for dry powder coating (7, 8). The LabRAM is a sophisticated bench-top mixer that exploits low frequency, high intensity, acoustic energy to rapidly fluidize and disperse as much as 500 g of a variety of materials. The RAM uses acoustic energy to mix the desired media through an oscillating mechanical driver that accelerates the mixing vessel by as much as 100 times the acceleration of gravity. The propagation of mechanical energy through a system of plates, weights, and springs creates an acoustic pressure wave in the mixing vessel. The frequency of the driver is optimized by the control system so that the system operates at resonance. By operating at resonance, the acoustic energy is absorbed by the media. The efficient mixing is accomplished by creating a homogenous shear zone throughout the mixing vessel without imparting excess energy and without the aid of mixing media or impellers. This approach seems promising because the RAM can mix at high acceleration and amplitude and therefore induce significant shear strain within the bulk powder in a short time. Related work by Davé and coworkers has demonstrated that when high degrees of shear are induced (e.g., by impact coaters) to disperse fine particles, the particles preferentially adhere to the surface of larger host particles after processing (2, 3, 5).

In this study, the RAM was evaluated as a tool for applying various dry powder coatings, such as silicon dioxide, to pharmaceutical excipients and APIs. The effect of these coatings on powder bulk density, particle size, and shear cell flow performance were used as indicators of performance enhancement, and the results were compared to those of dry powder coating using a comil.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
21%
To all process for new products only
13%
To select process for new products only
26%
To select processes for both new and legacy products
21%
Do not use QbD
21%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here